Skip to main content

Marijuana active ingredient extend rejection of incompatible organs

 

 

academics

 

Clinical research courses

Marijuana may be used to delay rejection of an incompatible organ where transplanted organs may not be a perfect match, says a new research. The findings suggest that THC, the active ingredient in marijuana, might prove to be a useful anti-rejection therapy. The study was published in the Journal of Leukocyte Biology.

"We are excited to demonstrate for the first time that cannabinoid receptors play an important role in the prolongation of rejection of a foreign graft by suppressing immune response in the recipient," said one of the researchers Mitzi Nagarkatti from University of South Carolina School of Medicine in the US.

To make this discovery, Nagarkatti and colleagues used two groups of mice that were genetically different, and transplanted skin from one group to the other.  All of the mice received incompatible skin, but one group was treated with a placebo and the other was treated with THC. The scientists observed that the rejection of the skin graft in mice that received THC was delayed when compared to the control group that only received a placebo.

The researchers, however, cautioned that transplant patients should not use marijuana as a therapy without the consent of their physician and should only do so in compliance with any and all local, state and federal laws.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>